Trial reportCell transplantation2017
ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and Design.
Trial report in Cell transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 93 citations in OpenAlex.
- Effect of cardiosphere-derived cells on segmental myocardial function after myocardial infarction: ALLSTAR randomised clinical trial.Open heart · 2021Trial
- Review
- A comprehensive review of clinical trials and Progress in stem cell therapies for advanced heart failure.Regenerative therapy · 2025Review
- Generation and applications of cardiac spheroids.npj biomedical innovations · 2025Review
- Stem Cell Therapy for Myocardial Infarction Recovery: Advances, Challenges, and Future Directions.Biomedicines · 2025Review
- Screening and characterization of natural extracts as dual-functional regulators for cardiomyocyte regeneration and cardiac repair.Frontiers in cardiovascular medicine · 2025Article
- Biomimetic nanomaterials in myocardial infarction treatment: Harnessing bionic strategies for advanced therapeutics.Materials today. Bio · 2024Review
- Challenges and future scope of exosomes in the treatment of cardiovascular diseases.The Journal of physiology · 2023Review
- Article
- Isoproterenol pre-treatment improve the therapeutic efficacy of cardiosphere-derived cells transplantation for myocardial infarction.Journal of thoracic disease · 2023Article
- Extracellular Vesicles and Pathological Cardiac Hypertrophy.Advances in experimental medicine and biology · 2023Article
- The Role of the Notch Signaling Pathway in Recovery of Cardiac Function after Myocardial Infarction.International journal of molecular sciences · 2022Review
- Myocardial regeneration protocols towards the routine clinical scenario: An unseemly path from bench to bedside.EClinicalMedicine · 2022Review
- Cell therapy in patients with heart failure: a comprehensive review and emerging concepts.Cardiovascular research · 2022Review
- Human Cardiac Progenitor Cell-Derived Extracellular Vesicles Exhibit Promising Potential for Supporting Cardiac RepairFrontiers in physiology · 2022Article
- Mini review: Biomaterials in repair and regeneration of nerve in a volumetric muscle loss.Neuroscience letters · 2021Review
- Review
- The Potential Properties of Natural Compounds in Cardiac Stem Cell Activation: Their Role in Myocardial Regeneration.Nutrients · 2021Review
- Quantitative Hybrid Cardiac [Molecular therapy. Methods & clinical development · 2020Article
- Extracellular vesicles - mediating and delivering cardioprotection in acute myocardial infarction and heart failure.Conditioning medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autologous cardiosphere-derived cells (CDCs) were the first therapeutic modality to demonstrate myocardial regeneration with a decrease in scar size and an increase in viable, functional tissue. Widespread applicability of autologous CDC therapy is limited by the need for patient-specific myocardial biopsy, cell processing, and quality control, resulting in delays to therapy and inherent logistical and economic constraints. Preclinical data had demonstrated equivalent efficiency of allogeneic to autologous CDCs. The ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) trial is a multicenter randomized, double-blind, placebo-controlled phase 1/2 safety and efficacy trial of intracoronary delivery of allogeneic CDCs (CAP-1002) in patients with myocardial infarction (MI) and ischemic left ventricular dysfunction. The phase 1 safety cohort enrolled 14 patients in an open-label, nonrandomized, dose-escalation safety trial. The phase 2 trial is a double-blind, randomized, placebo-controlled trial that will compare intracoronary CDCs to placebo in a 2:1 allocation and will enroll up to 120 patients. The primary endpoint for both phases is safety at 1 month. For phase 2, the primary efficacy endpoint is relative change from baseline in infarct size at 12 months, as assessed by magnetic resonance imaging. The ALLSTAR trial employs a "seamless" WOVE 1 design that enables continuous enrollment from phase 1 to phase 2 and will evaluate the safety of intracoronary administration of allogeneic CDCs and its efficacy in decreasing infarct size in post-MI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.